PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23972517-3	2013	The results showed that Wnt5a augmented the effects of Imatinib Mesylate on inhibiting CML cells proliferation and inducing apoptosis in vitro; Wnt5a enhanced the inhibition effect of Imatinib Mesylate on the growth of K562 cells xenograft tumour in an animal model.	Imatinib Mesylate	55-72	Wnt family member 5A	Homo sapiens	24-29	
23972517-0	2013	Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and gamma-catenin inhibition.	Imatinib Mesylate	44-61	Wnt family member 5A	Homo sapiens	0-5	
23972517-2	2013	The research is aimed at determining whether Wnt5a affects the effects of Imatinib Mesylate against BCR-ABL positive CML cells (K562 cells and KU812 cells) and which signalling proteins are involved in.	Imatinib Mesylate	74-91	Wnt family member 5A	Homo sapiens	45-50	
23972517-3	2013	The results showed that Wnt5a augmented the effects of Imatinib Mesylate on inhibiting CML cells proliferation and inducing apoptosis in vitro; Wnt5a enhanced the inhibition effect of Imatinib Mesylate on the growth of K562 cells xenograft tumour in an animal model.	Imatinib Mesylate	184-201	Wnt family member 5A	Homo sapiens	144-149	
23972517-5	2013	When inhibiting the activity of JNK, the influence of Wnt5a on the effects of Imatinib Mesylate was attenuated.	Imatinib Mesylate	78-95	Wnt family member 5A	Homo sapiens	54-59	
23972517-7	2013	These results suggest that Wnt5a can enhance the efficacy of Imatinib Mesylate through JNK/beta-catenin/Survivin and gamma-catenin/beta-catenin/Survivin pathways.	Imatinib Mesylate	61-78	Wnt family member 5A	Homo sapiens	27-32	
18407462-6	2008	In addition, Wnt5a increased the nuclear beta-catenin level and treatment with imatinib or ionomycin, either of which blocks the beta-catenin pathway, reduced the anti-apoptotic activity of Wnt5a, together suggesting the simultaneous involvement of the beta-catenin-mediated pathway in the Wnt5a anti-apoptotic activity.	Imatinib Mesylate	79-87	Wnt family member 5A	Homo sapiens	190-195	
18407462-6	2008	In addition, Wnt5a increased the nuclear beta-catenin level and treatment with imatinib or ionomycin, either of which blocks the beta-catenin pathway, reduced the anti-apoptotic activity of Wnt5a, together suggesting the simultaneous involvement of the beta-catenin-mediated pathway in the Wnt5a anti-apoptotic activity.	Imatinib Mesylate	79-87	Wnt family member 5A	Homo sapiens	190-195